Recommended

Learn how to optimize antibody leads in early drug discovery in this upcoming webinar – register today
Discover how to overcome low affinity or poor TCR yields that are slowing you down in this upcoming webinar – register your details today
Unlock the science, strategy and real-world impact behind the next generation of precision therapies – access our new brand report now >>
Safety data is no longer just a regulatory checkbox – it’s a strategic advantage. Find out more in our upcoming webinar, register your details today
Explore how AI is reshaping early drug discovery, from target identification and compound screening to predictive modelling and trial design – register now!
news

Protease inhibitor aprotinin shows promise against SARS-CoV-2 in cells

Researchers have found that aprotinin, an approved drug for influenza in Russia, combats SARS-CoV-2 in cells.

SARS-CoV-2

Researchers have newly identified a drug which they say has the potential to provide a treatment for SARS-CoV-2, the coronavirus causing the COVID-19 pandemic. The study was conducted by scientists at the University of Kent, UK, and the Goethe-University in Frankfurt am Main and the Hannover Medical School, both Germany.

The international team found that the approved protease inhibitor named aprotinin displayed activity against SARS-CoV-2 in pre-clinical trials. The drug was tested in different cell types including Caco2, Calu-3 and primary bronchial epithelial cell air–liquid interface cultures, as well as against four virus isolates.

The researchers revealed that the drug inhibits the entry of the virus into host cells by preventing the cleavage of the coronavirus Spike (S) protein by cellular proteases. The team say that following an analysis of proteomics and translatome data, the drug may compensate for the loss of host cell protease inhibitors that are downregulated upon SARS-CoV-2 infection.

 

Reserve your FREE place

 


Are low affinity or poor TCR yields slowing you down?

Explore how CHO expression of soluble TCRs and TCR affinity maturation workflows via phage, serving as essential building blocks for early-stage TCR-TCE candidate generation.

22 October 2025 | 16:00 PM BST | FREE Webinar

Join Jiansheng Wu, Ph.D. to explore two integrated strategies:

  • High-titer CHO-based expression of sTCRs (~100 mg/L), enabling scalable and high-throughput production
  • Optimized phage display affinity maturation, improving TCR binding by up to ~10,000-fold

Whether you’re starting a new TCR program or optimizing an existing platform, this session will offer actionable strategies to accelerate discovery and improve candidate quality.

Register Now – It’s Free!

 

The group also found that aprotinin could combat SARS-CoV-2 in concentrations that are achieved in patients, suggesting that it would be safe to take.  

The team highlight that aprotinin aerosols are approved in Russia for the treatment of influenza and could be readily tested for the treatment of COVID-19. Therefore, they conclude that therapeutic aprotinin concentrations exert anti-SARS-CoV-2 activity and an approved aprotinin aerosol may have potential for the early local control of coronavirus replication and the prevention of COVID-19 progression to a severe, systemic disease.

Persistence of infected cells in lungs could explain long-term COVID-19 symptoms, say scientists…

Professor Martin Michaelis, one of the lead researchers, said: “The aprotinin aerosol has been reported to be tolerated extremely well in influenza patients. Hence, it may have a particular potential to prevent severe COVID-19 disease when applied early after diagnosis.”

The study was published in the journal Cells.